OGN Stock Forecast: Organon & Co. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Organon & Co. hold a median 12-month price target of $9 — -35.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Organon & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Revisions (54): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −35.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | BNP Paribas | Downgrade | Neutral | $12 → $14 |
| 28 Apr 2026 | Piper Sandler | Upgrade | Neutral | $5.00 → $14 |
| 24 Feb 2026 | Barclays | Maintains | Underweight | — |
| 9 Dec 2025 | Barclays | Initiates | Underweight | — |
| 11 Nov 2025 | JP Morgan | Maintains | Underweight | — |
| 11 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 Feb 2025 | Barclays | Maintains | Overweight | — |
| 14 Feb 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 Sept 2024 | JP Morgan | Downgrade | Underweight | — |
| 6 May 2024 | Goldman Sachs | Maintains | Neutral | — |
| 3 May 2024 | Goldman Sachs | Maintains | Neutral | — |
| 29 Apr 2024 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2024 | Goldman Sachs | Maintains | Neutral | — |
| 22 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 3 Nov 2023 | Goldman Sachs | Downgrade | Neutral | — |
| 25 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 11 Oct 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OGN.
This page is one stock. Monday covers all of them.
OGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Organon & Co. returned +96.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 17.8×
- Price / sales
- 0.6×
- Price / book
- 3.1×
- EV / EBITDA
- 6.9×
Cheaper than 49% of US stocks
Cheaper than 76% of US stocks
Cheaper than 30% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- −1.7%
- Earnings growth (YoY)
- 2.5%
- Gross margin
- 54.4%
- Operating margin
- 19.8%
- Net margin
- 3.5%
Higher than 26% of US stocks
Higher than 40% of US stocks
Higher than 67% of US stocks
Higher than 79% of US stocks
Higher than 53% of US stocks
- Return on equity
- 20.3%
- Return on assets
- 5.6%
- Dividend yield
- 0.6%
Higher than 81% of US stocks
Higher than 79% of US stocks
Higher than 9% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Organon & Co. has a market value of $3.6B and an enterprise value of $10.7B.
Revenue in the twelve months to 30 June 2026: $6.1B. The latest quarter shrank 2.3% year on year.
Net income over the same four quarters: $209.0M, a 3.4% net margin.
Diluted earnings per share, trailing twelve months: $0.77.
Free cash flow in the twelve months to 30 June 2026: $434.0M, after $170.0M of capital spending.
Organon & Co. spent $18.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 17.8×; forward P/E: 3.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.58%, paying out 10% of earnings.
Organon & Co. employs 10,000 people — $613K of revenue per employee.
Data provided by Twelve Data
OGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| OGNOrganon & Co. | $3.6B | 92 |
| ZOARZoar Ltd. | $608.4M | 18 |
| BIIBBiogen, Inc. | $36.9B | 79 |
| NVSTEnvista Holdings Corp.* | $3.7B | 96 |
| CDNACareDx, Inc.* | $3.6B | 92 |
| TARSTarsus Pharmaceuticals, Inc.* | $3.6B | 72 |
| CRSPCRISPR Therapeutics AG* | $3.8B | 33 |
* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.
Take a look at OGN’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Organon & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OGN
What is the OGN stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Organon & Co. have a median 12-month price target of $9, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OGN stock a buy right now?
Of the 4 analysts covering Organon & Co., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Organon & Co. 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OGN?
As at 21 Nov 2026, Organon & Co. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
Will OGN stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies -35.2% from the last close, and Ticker Nerd's factor model ranks Organon & Co. 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OGN stock forecast for 2030?
No analyst covering Organon & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
How has OGN stock performed over the past year?
Organon & Co. returned +96.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Organon & Co. do?
Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine.
About Organon & Co.
Organon & Co. is a global pharmaceutical company focused on women’s health, biosimilars, and established prescription medicines. Organon & Co. develops and delivers health solutions across a broad portfolio that includes therapies and medical devices used in reproductive health, contraception, fertility, dermatology, cardiovascular care, respiratory conditions, and other areas of general medicine. The company serves patients and healthcare providers in more than 140 markets through wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its women’s health business is a central part of the portfolio, supported by biosimilars and well-known legacy brands that address everyday treatment needs across multiple therapeutic areas. Organon & Co. operates as a diversified healthcare provider with a strong international footprint and a product mix designed to meet ongoing demand for prescription treatments and essential medicines.
CEO Mr. Kevin Ali · 10,000 employees · United States · https://www.organon.com